GlobeNewswire: Vical Incorporated Contains the last 10 of 294 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T12:45:37ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/08/30/1909218/0/en/Vical-Stockholders-Approve-Reverse-Stock-Split-and-Merger-with-Brickell.html?f=22&fvtc=4&fvtv=6457Vical Stockholders Approve Reverse Stock Split and Merger with Brickell2019-08-30T15:54:51Z<![CDATA[• Merger Transaction Expected to Close August 31, 2019]]>https://www.globenewswire.com/news-release/2019/06/03/1862969/0/en/Vical-and-Brickell-Announce-Merger-Agreement.html?f=22&fvtc=4&fvtv=6457Vical and Brickell Announce Merger Agreement2019-06-03T07:00:00Z<![CDATA[SAN DIEGO and BOULDER, Colo., June 03, 2019 (GLOBE NEWSWIRE) -- Vical Incorporated (“Vical”) (Nasdaq:VICL) and Brickell Biotech, Inc. (“Brickell”), a privately-held clinical-stage medical dermatology company, today announced they entered into a definitive merger agreement (the “Merger”) under which Brickell would merge with a wholly-owned subsidiary of Vical in an all-stock transaction. The Merger would create a pharmaceutical company focused on developing novel and differentiated prescription therapies addressing unmet patient needs in hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other debilitating dermatologic disorders. Brickell’s lead pipeline asset, sofpironium bromide, is a pivotal Phase 3-ready topical soft anticholinergic intended for axillary hyperhidrosis. Brickell’s development partner, Kaken Pharmaceutical, Co, LTD (“Kaken”), has reported positive Phase 3 results in a clinical trial conducted in Japan. Upon closing of the transaction, the combined company would operate under the name, Brickell Biotech, Inc. and trade on the Nasdaq Capital Market under a new ticker symbol still to be determined.]]>https://www.globenewswire.com/news-release/2019/02/19/1737984/0/en/Vical-to-Discontinue-Clinical-Development-of-VL-2397-as-it-Considers-Near-Term-Strategic-Alternatives.html?f=22&fvtc=4&fvtv=6457 Vical to Discontinue Clinical Development of VL-2397 as it Considers Near Term Strategic Alternatives2019-02-19T22:45:00Z<![CDATA[SAN DIEGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that it has decided to discontinue the Phase 2 clinical trial of VL‑2397 that was initiated in the first quarter of 2018. The decision was based on the Company’s decision to conserve its cash resources while it pursues its strategic alternative review process, as well as low patient accrual rates. The Phase 2 clinical trial was evaluating VL-2397 as a potential first-line treatment for invasive aspergillosis in immunocompromised adults with acute leukemia or recipients of an allogeneic hematopoietic cell transplant.]]>https://www.globenewswire.com/news-release/2018/10/29/1638103/0/en/Vical-Reports-Third-Quarter-2018-Financial-and-Operational-Results.html?f=22&fvtc=4&fvtv=6457Vical Reports Third Quarter 2018 Financial and Operational Results2018-10-29T10:30:00Z<![CDATA[SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended September 30, 2018. Net loss for the third quarter of 2018 was $1.5 million, or $0.07 per share, compared with a net loss of $3.1 million, or $0.27 per share, for the third quarter of 2017. Revenues for the third quarter of 2018 were $0.1 million, compared with revenues of $3.2 million for the third quarter of 2017, reflecting a reduction in revenues from Astellas Pharma Inc. for services performed under ASP0113 collaborative agreements. Net loss for the third quarter of 2018 included a gain of $2.3 million related to the sale of the Company’s manufacturing assets and $0.7 million received from Astellas to cover close down costs related to the ASP0113 program.]]>https://www.globenewswire.com/news-release/2018/08/23/1555735/0/en/Vical-to-Present-at-the-20th-Annual-Rodman-Renshaw-Global-Investment-Conference.html?f=22&fvtc=4&fvtv=6457Vical to Present at the 20th Annual Rodman & Renshaw Global Investment Conference2018-08-23T12:00:00Z<![CDATA[SAN DIEGO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, September 5, at 11:40 a.m. ET at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018, at the St. Regis New York Hotel in New York City. A webcast of the company’s presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.]]>https://www.globenewswire.com/news-release/2018/08/07/1547895/0/en/Vical-Reports-Second-Quarter-2018-Financial-and-Operational-Results.html?f=22&fvtc=4&fvtv=6457Vical Reports Second Quarter 2018 Financial and Operational Results2018-08-07T10:30:00Z<![CDATA[SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended June 30, 2018. Net loss for the second quarter of 2018 was $4.9 million, or $0.22 per share, compared with a net loss of $3.3 million, or $0.30 per share, for the second quarter of 2017. Revenues for the second quarter of 2018 were $0.7 million, compared with revenues of $3.4 million for the second quarter of 2017, reflecting a decline in revenues from Astellas Pharma Inc. for services performed under ASP0113 collaborative agreements.]]>https://www.globenewswire.com/news-release/2018/07/19/1539402/0/en/Vical-Announces-Review-of-Potential-Strategic-Transactions.html?f=22&fvtc=4&fvtv=6457Vical Announces Review of Potential Strategic Transactions2018-07-19T10:00:00Z<![CDATA[SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that its Board of Directors plans to explore a range of strategic options to enhance shareholder value. The company has retained MTS Health Partners, L.P. as its financial advisor to assist in the strategic review process.]]>https://www.globenewswire.com/news-release/2018/06/11/1519433/0/en/Vical-Reports-Phase-2-Trial-of-HSV-2-Therapeutic-Vaccine-Did-Not-Meet-Primary-Endpoint.html?f=22&fvtc=4&fvtv=6457Vical Reports Phase 2 Trial of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint2018-06-11T10:00:00Z<![CDATA[Company to focus on advancing VL-2397 and other pipeline opportunities Company to focus on advancing VL-2397 and other pipeline opportunities]]>https://www.globenewswire.com/news-release/2018/05/03/1495712/0/en/Vical-Reports-First-Quarter-2018-Financial-and-Operational-Results.html?f=22&fvtc=4&fvtv=6457Vical Reports First Quarter 2018 Financial and Operational Results2018-05-03T10:30:00Z<![CDATA[SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended March 31, 2018. Net loss for the first quarter of 2018 was $6.3 million, or $0.29 per share, compared with a net loss of $2.8 million, or $0.25 per share, for the first quarter of 2017. Revenues for the first quarter of 2018 were $0.7 million, compared with revenues of $3.2 million for the first quarter of 2017, reflecting revenues from Astellas Pharma Inc. for services performed under ASP0113 collaborative agreements.]]>https://www.globenewswire.com/news-release/2018/04/26/1488603/0/en/Vical-Announces-News-Release-and-Conference-Call-Schedule-for-First-Quarter-2018-Financial-Results.html?f=22&fvtc=4&fvtv=6457Vical Announces News Release and Conference Call Schedule for First Quarter 2018 Financial Results2018-04-26T20:05:00Z<![CDATA[SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended March 31, 2018, before the opening of trading on Thursday, May 3, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, May 3. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on development programs in the conference call and webcast.]]>